<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378179</url>
  </required_header>
  <id_info>
    <org_study_id>55057</org_study_id>
    <nct_id>NCT04378179</nct_id>
  </id_info>
  <brief_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS)</brief_title>
  <official_title>Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francois Haddad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precordior Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure (HF) is a syndrome where the heart is unable to pump or fill adequately to meet
      the circulatory needs of the body. The main purpose of this study is to test the ability a
      novel wearable sensor device (Suunto Movesense sensor), positioned on the chest which
      measures the movements and function of the heart, in combination with a smartphone app
      (Precordior CardioSignal app), to identify patients with different types of heart failure and
      their characteristics, as compared with clinical diagnosis. Echocardiography will also be
      used to confirm changes in cardiac cardiac mechancis including strain, cardiac torsion,
      diastolic filling characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HF detection</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>The ability of the Precordior sensor to detect heart failure with reduced and preserved ejection fraction as compared to control participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of differences in myocardial mechanics</measure>
    <time_frame>14 weeks</time_frame>
    <description>The ability of the Precordior sensor to detect differences in myocardial mechanics as defined my myocardial strain and torsion analysis.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>HF patients with preserved ejection fraction (HFpEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>HF patients with reduced ejection fraction (HFrEF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF but meet other inclusion criteria and non of the exclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting Stanford Hospital and Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage B or C heart failure. Participants with heart failure will have a
             diagnosis of heart failure with reduced ejection fraction (HFrEF) or preserved
             ejection fraction (HFpEF), as corresponding to each target patient group.

          -  Controls will be patients matched for age, sex, BMI and without evidence of
             subclinical heart failure. Control patients will be enrolled from elective patients
             referred to Stanford inpatient or outpatient echocardiographic laboratory, who are not
             diagnosed with HFpEF or HFrEF.

        Exclusion Criteria:

          -  Patients incompetent to make informed decisions and unable to provide written consent

          -  Severe cardiac valvular heart disease or previous prosthetic cardiac valve

          -  Pericardial disease including constrictive pericarditis, or moderate or large
             pericardial effusion

          -  Mechanical circulatory support or Heart and/or lung transplant recipients

          -  Major cardiovascular adverse event or surgery within 6 weeks pf planned study
             enrollment

          -  Patients with pacemaker

          -  Chest wall disease, severe pectus excavatum

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francois Haddad, MD</last_name>
    <phone>650-799-0373</phone>
    <email>fhaddad@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myraim Amsallem, MD PhD</last_name>
    <email>mamsalle@stanford.edu</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Francois Haddad</investigator_full_name>
    <investigator_title>Clinical Professor Medicine - Med/Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

